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 ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not 
Pancrelipase Delayed Release Capsule (Creon) is safe for use in patients’ ≥7 years old who 
suffer from pancreatic insufficiency due to cystic fibrosis.  
 
Study Design: Systemic review of 3 English language primary studies, published between 2000-
2010. 
 
Data Sources: Two double blind randomized controlled trials (RCTs) as well as an open label 
phase study with a double blind phase comparing the safety of Pancrelipase Delayed Release 
Capsule (Creon) in treating pancreatic insufficiency in those suffering from Cystic Fibrosis. 
These studies were found using Cochrane Systematic Reviews and PubMed.  
 
Outcomes Measured: The outcomes of each study measured the safety and tolerability of Creon 
by monitoring vital signs, weight, BMI, safety laboratory values, and adverse events. Adverse 
events were tracked in all studies.   
 
Results: Graff et al demonstrated that for every three participants who took Creon, there was one 
fewer incidence of Treatment Emergent Adverse Events (TEAE’s) than in the group of 
participants taking the placebo. TEAE’s were reported in 5 patients (29.4%) while taking Creon 
and in 9 patients (53.6%) while receiving the placebo. There were also no discontinuations due 
to treatment adverse events and no serious adverse events noted during the trial. Trapnell et al 
demonstrated that for every four participants who took Creon there was one fewer incidence of 
TEAE’s than in the group of participants taking the placebo. Stern et al demonstrated that during 
the double blind phase in both the adult and pediatric/adolescent studies, higher percentages of 
placebo-treated patients (67% and 70% respectively) reported treatment emergent adverse events 
than Creon treated patients (39% and 61% respectively). 
 
Conclusion: Creon does appear to be safe and tolerable for those over the age of 7 suffering 
from pancreatic insufficiency due to cystic fibrosis. The TEAE’s reported in each study proved 
the tolerance of Creon to surpass that of other treatment modalities. These studies also address 
the other benefits of Creon in allowing for significant improvements in stool fat, weight, and 
nitrogen and a significant reduction in daily stool frequency. Although these are promising 
results more RCTs must be conducted with wider age groups in order to compare the safety of 
Creon.  
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INTRODUCTION 
 
Cystic fibrosis is a hereditary disorder affecting the exocrine glands causing the 
production of abnormally thick mucus, leading to the blockage of pancreatic ducts, intestines, 
and bronchi and often resulting in respiratory infections.
1
 Exocrine pancreatic insufficiency (EPI) 
is defined as the lack of digestive enzymes secreted by the pancreas in association with diseases 
such as cystic fibrosis which leads to maldigestion, with resultant malabsorption of fat, protein, 
and fat soluble vitamins which ultimately leads to malnutrition.
2
 Approximately 85% of patients 
diagnosed with cystic fibrosis also have EPI. The symptoms begin in newborns shortly after birth 
and increase throughout infancy.
2
 Approximately 90% of patients with EPI are treated with 
pancreatic enzyme replacement therapy to maintain adequate nutrition.
2
 If EPI is left untreated, 
the subsequent malnutrition and debilitating symptoms may lead to poor growth, poor weight 
gain, and failure to thrive especially for those with cystic fibrosis.
2 
Cystic fibrosis is the most common autosomal genetic disease among white persons and 
has a prevalence of 1 in 2,500 newborn infants.
3
 The only risk factor for cystic fibrosis is a 
family history of the condition. The mean annual healthcare cost for treating cystic fibrosis in the 
United States is $48,098 which is more than 22 times the average of $2,172 for people without 
cystic fibrosis.
4
 Medical expenditures for people with cystic fibrosis increase with age through 
childhood and plateau during and after the teenage years.
4 
A study shows that adults with cystic fibrosis average about 12 office visits per year. 
Despite the monthly contact with physicians, 33% of patients have at least one inpatient stay per 
year.
5
 Individuals with cystic fibrosis have mean annual expenditures for inpatient care that are 
35 times higher ($16, 545 vs. $467) than those for people without cystic fibrosis.
4
 This was due 
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primarily to the greater number of inpatient admissions among those in the cystic fibrosis group. 
The average expenditure for outpatient visits are 10 times higher ($13,092 vs. $1,267) for those 
with cystic fibrosis than individual’s without.4 Not only are hospital admissions and healthcare 
costs higher for those with cystic fibrosis, but one of the biggest monetary burdens is prescribed 
medications. The average annual expenditures for prescribed medications were 42 times higher 
($18,461 vs. $437) among those with cystic fibrosis.
4
      
Cystic fibrosis is an autosomal recessive disease caused by abnormalities of the cystic 
fibrosis transmembrane conductance regulator (CFTR) chloride conductance channel and affects 
the function of the exocrine glands in multiple organs, including the lungs, liver, pancreas, 
intestines, and skin.
5
 The disease is characterized by malabsorption, gastrointestinal 
abnormalities, infertility, and severe progressive sinopulmonary disease.
5
 Differences in disease 
patterns seen in individuals and families probably result from the combined effects of the 
particular mutation and various, but still unknown, factors in the patient and his or her 
environment.
6
 Despite the great advances in research, there is still no cure for cystic fibrosis due 
to these genetic changes and mutations.   
There are numerous treatment options for individuals suffering from cystic fibrosis, each 
of which targets a different symptomology caused by the disease. The main treatments for lung 
problems in people with cystic fibrosis focus on antibiotics for infections of the airways, chest 
physical therapy, and exercise. The antibiotics used are: Tobramycin, Colistin, and 
Azithromycin.
7
 Chest physical therapy requires the individual to pound their chest and back over 
and over in order to dislodge the mucus within their lungs. Patients are encouraged to perform 
aerobic exercise in order to loosen their mucus and encourage coughing to clear the mucus build 
up in the lungs. Surgeries are a common occurrence for those suffering from cystic fibrosis and 
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range from nasal polyp removal to lung transplants. One of the hardest components of the 
disease to treat are digestive complications. Patients are treated with oral pancreatic enzymes to 
help them digest fats and proteins and to assist in the absorption of vitamins.   
Although there are several drugs that aid those with EPI, Creon has been approved for 
those with cystic fibrosis. Pancreatic enzyme replacement therapy is critical for adequate 
nutrition in patients with cystic fibrosis with EPI.  Thus far, numerous studies have been 
conducted and results show that Creon is a safe treatment for EPI due to cystic fibrosis. Creon 
allows patients significant improvements in stool fat, weight gain, and absorption of nutrients 
due to its ability to break down fats, proteins, and carbohydrates.  
 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “Is Pancrelipase 
Delayed Release Capsule (Creon) safe for use in patients’ ≥7 years old who suffer from 
pancreatic insufficiency due to cystic fibrosis.” 
 
METHODS 
The criteria used for the selection of the 3 studies included that patients be either male or 
female over the age of 7 with cystic fibrosis causing exocrine pancreatic insufficiency. The 
studies involved the interventional use of either Creon 12,000 Units or 24,000 units. The 
comparison groups in the two RCTs received either Creon or a visually matched placebo. In the 
double blind phase study a group was given Creon while a subgroup was given either Creon or a 
placebo. The outcomes measured in the 3 studies included the safety and tolerability of Creon for 
the treatment of exocrine pancreatic insufficiency due to cystic fibrosis using the incidence of 
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treatment emergent adverse events (TEAEs) for statistical analysis. The three studies included 
consist of two randomized, double blind, placebo controlled studies, two period crossover 
clinical trials (RCTs) and one open label phase study with a double blind phase.  
Keywords used to search for the articles included “cystic fibrosis”, “Creon”, and 
“pancreatic insufficiency”. All articles were originally published in peer-reviewed journals in the 
English language. Data was researched and collected by the author using articles from 2000-
2010 in PubMed and the Cochrane library. Articles were selected based on relevance to the 
clinical question and whether they included patient oriented evidence that matters (POEMS). All 
articles chosen for this review were peer-reviewed and published in well-known journals such as 
Journal of Clinical Therapeutics, The American Journal of Gastroenterology, and the Journal of 
Cystic Fibrosis. Inclusion criteria consisted of the requirement that studies that were RCTs or 
clinical trials published after 1996 in which no other systematic reviews, meta-analysis, or 
review article was found on the Cochrane database answering the same question with additional 
criteria found in Table 1. Exclusion criteria included studies in which patients under 7 years old 
were utilized. The statistics used to evaluate patient outcomes included p values, RRI, ARI, CI, 
and NNH. The demographics and characteristics of the individuals included in these studies are 
displayed in table 1. 
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Table 1 - Demographics & Characteristics of included studies (Table 1) 
 
 
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Graff, 
2010 
(2) 
RCT 17 7 to 11 
years 
old  
-confirmed diagnosis of CF 
2 positive sweat tests and/or 
disease causing mutations 
detected on CF 
transmembrane conductance 
regulator gene analysis  
-confirmed diagnosis of 
enzymatic pancreatic 
insufficiency (EPI) defined 
as a coefficient of fat 
absorption (CFA) <70% 
without pancreatic enzyme 
supplementation or as 
human fecal elastase 
<50ug/g (measured within 
the past 12 months) 
-must have been receiving 
treatment with a 
commercially available 
PERT product as a stable 
dose for >3 months  
-if patient had severe 
medical conditions that 
limit participation  
-if they had undergone 
any recent major surgery  
-Ileus or acute abdomen 
malignancy of the 
digestive tract 
(excluding pancreatic 
cancer), HIV, celiac/ 
Chron’s disease 
-known allergy to 
Pancrelipase or the 
inactive ingredients in 
Pancrelipase delayed 
release capsules, or 
exposure to an 
experimental drug 
within 30 days of the 
start of the study  
1 Creon 12,000 
units 
Stern, 
2000 
(8) 
Open 
label  
97 >18 
years of 
age and 
between 
7 and 18 
years of 
age 
-a diagnosis of CF 
documented by sweat 
chloride results (>70) and 
clinical symptoms of 
exocrine pancreatic 
insufficiency with a history 
of steatorrhea  
-patients must have been 
stabilized on a diet and dose 
of pancreatic enzyme 
supplementation  
-if a patient had extreme 
cachexia, severe acute or 
chronic pulmonary 
disease, or were using 
other gastrointestinal 
medications or 
medications affecting 
the gastrointestinal tract 
other than oral 
pancreatic enzymes 
21 Creon and high 
fat diet  
Trapnell, 
2009 
(9) 
RCT 34 12 years 
of age 
and 
older 
- a diagnosis of CF 
(confirmed by 2 positive 
chloride sweat tests and/or 
CFTR gene analysis) and 
EPI (confirmed by either a 
coefficient of fat absorption 
(CFA) <70% without 
supplementation or fecal 
elastase <50 ub/g stool 
within the past 12 months) 
-receiving treatment with a 
commercially available 
pancreatic enzyme product  
-if they had an ileus or 
acute abdomen, distal 
ileal obstruction 
syndrome within 6 
months of enrolment, 
gastrointestinal 
malignancy within 5 
years of enrollment, a 
history of pancreatitis or 
fibrosing colonopathy or 
known infection with 
HIV 
2 Creon 24,000 
units  
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OUTCOMES MEASURED 
 
 All of the outcomes measured were POEMS related to the safety and tolerability of Creon 
for the treatment of pancreatic insufficiency in those with cystic fibrosis. Outcomes were 
measured in a variety of ways and included vital signs, physical examination, weight, BMI, 
safety laboratory values, and adverse events.
2, 8, 9
 The safety of Creon was measured by treatment 
emergent adverse events (TEAEs) reported by the patients.
8, 9, 10
 The TEAEs monitored were 
gastrointestinal disorders, nervous system disorders, respiratory disorders, and skin/subcutaneous 
tissue disorders.
2, 8, 9
 Secondary efficacy outcomes were also assessed. These include the 
coefficient of nitrogen absorption (CAN), stool fat, stool weight, and clinical symptomatology.
2, 
8, 9
 Laboratory analyses using standard procedures were performed at Mayo Clinical Trial 
Services.
2, 8, 9
 
 
RESULTS 
 The three studies chosen evaluated the safety of Creon for the treatment of pancreatic 
insufficiency in individuals ≥7 years old suffering from cystic fibrosis. Two double blind 
randomized controlled trials (RCTs) as well as an open label phase study with a double blind 
phase were chosen for analysis.   
 The study conducted by Graff et al consisted of twenty three individuals, sixteen of 
whom completed the study. Inclusion and exclusion criteria for the study can be found in Table 
1.Each period during the 2-period crossover consisted of the patients receiving either Creon 
12,000 units or the identical placebo capsules for a total of five days. A variety of safety 
measures were monitored during the stud. These included: vital signs, physical examinations, 
standard laboratory safety tests (hematology and biochemistry), and adverse events. Treatment 
Creon Safety for Cystic Fibrosis 
   Shamloul   
 
7 
emergent adverse events were reported in 5 patients (29.4%) during receipt of Creon and in 9 
patients (56.3%) during receipt of placebo; these were predominantly gastrointestinal events. 
There were no discontinuations due to treatment emergent adverse events and no serious adverse 
events. Creon was also shown to provide significant improvements in stool fat, weight, and 
nitrogen and a significant reduction in daily stool frequency as compared with the placebo (p 
<0.001). The NNH was calculated to be -3 (Table 2) which indicates that for every three 
participants who took Creon, there was one fewer incidence of TEAE’s than in the group of 
participants taking the placebo.
2
 
 
Table 2. Analysis of Numbers Needed to Harm for Creon Use  
Graff (2010) CER EER RRI ARI NNH 
 56.3% 29.4% -48% -26.9% -3 
 
 The study conducted by Trapnell et al consisted of thirty four individuals, thirty two of 
whom completed the study. Inclusion and exclusion criteria for the study can be found in Table 
1. Each period during the 2-period crossover each period consisted of the patients receiving 
either Creon 24,000 units or the identical placebo capsules for a total of five days. A variety of 
safety measures were monitored during the study. These included: vital signs, physical 
examinations, standard laboratory safety tests (hematology and biochemistry), and adverse 
events. Physical examinations were performed during screening and at the end of each crossover 
period. Laboratory safety tests were performed during screening, at the end of the first crossover 
period, and at the beginning and end of the second crossover period. Treatment emergent adverse 
events and treatment related TEAEs had a lower overall incidence during Creon treatment than 
during placebo treatment (43.8% vs. 64.5%). Analysis of adverse events did not reveal any 
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TEAEs with a greater clinically meaningful incidence in the Creon group compared with the 
placebo group, and no cases of hypersensitivity were reported. Creon was also shown to provide 
significant improvements in stool fat, weight, and nitrogen and a significant reduction in daily 
stool frequency as compared with the placebo (p <0.001 for all). The NNH was calculated to be -
4 (Table 3) which indicates that for every four participants who took Creon, there was one fewer 
incidence of TEAE’s than in the group of participants taking the placebo.9 
 
Table 3. Analysis of Numbers Needed to Harm for Creon Use 
Trapnell (2009) CER EER RRI ARI NNH 
 64.5% 43.8% -32.1% -20.7% -4 
 
 The study conducted by Stern et al consisted of ninety seven individuals, seventy four of 
whom completed the study. Of those seventy four patients, thirty six were adults and thirty eight 
were pediatrics/adolescents. Inclusion and exclusion criteria for the study can be found in Table 
1. During the open label phase study and the double blind phase study patients received either 
Creon or the identical placebo capsules for a total of five to seven days. Tolerance was assessed 
by physical examination, adverse events, vital signs, urinalysis, and serum biochemistry and 
hematology evaluations. During the open label phase, 52% of the adult patients and 64% of the 
pediatric/adolescent patients reported at least one treatment emergent adverse event. During the 
double blind phase in both the adult and pediatric/adolescent studies, higher percentages of 
placebo-treated patients (67% and 70% respectively) reported treatment emergent adverse events 
than Creon treated patients (39% and 61% respectively). Creon was also shown to provide 
significant improvements in stool fat, weight, and nitrogen and a significant reduction in daily 
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stool frequency as compared with the placebo (p <0.001 for all). The NNH could not be 
calculated for this study due to the lack of control throughout the duration of the trail.
8
 
 
 
DISCUSSION 
 The results from these studies demonstrate that Creon therapy is a safe and effective 
treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis. Although none of 
the studies compared Creon to any other EPI drug, these early studies show promising results in 
terms of efficacy and safety. In all three studies the adverse events were minimal and the 
reported TEAE’s proved to be minuscule. Creon treated patients demonstrated significantly 
superior results compared with placebo treated patients for coefficient of fat absorption, stool 
frequency, stool consistency, and coefficient of nitrogen absorption.
2, 8, 9
  
 Although these studies yielded important results, there were limitations that need to be 
addressed. The number of patients employed in each study was very low. By enrolling more 
participants results gathered are more efficacious. In addition, trials need to be completed with 
individuals suffering from cystic fibrosis who are under the age of seven. This will allow for the 
investigation of the efficacy of Creon in pediatric and neonatal patients. Another limitation that 
can be addressed is the duration of the studies. All three studies lasted only five to seven days. In 
order to gain better results, longitudinal analyses must be conducted.  
 Creon is also used for other conditions that cause pancreatic insufficiency. These 
conditions include chronic pancreatitis, cystic fibrosis, pancreatic cancer, post pancreatectomy, 
and post- gastrointestinal bypass surgery.
10
 Due to the wide use of Creon, it is commonly 
covered by most insurance companies. There are also Patient Assistance Programs that help 
supply the drug for free or at a reduced cost for its customers. However, for those individuals 
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without insurance the cost of 90 capsules of Creon totals about $500.
11
 Such an elevated cost can 
truly hinder a patient’s ability to afford a vital medication for their wellbeing.  
 
CONCLUSION 
This review and chosen studies show that Creon is a safe treatment for pancreatic 
insufficiency in individuals with cystic fibrosis who are  ≥7 years of age. No serious or life 
threatening adverse events were reported related to the use of Creon during these studie. None of 
the studies reported any deaths when the use of Creon even when extremely high doses (24,000 
Units).  
Due to the limited amount of studies, small sample sizes, and very few comparison 
studies, future studies are needed to directly compare Creon with other EPI drugs in order to test 
efficacy and safety. Also, future research should include longer treatment durations to more 
definitively evaluate the benefits and risks of treating cystic fibrosis patients with Creon.    
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